Electrochemical biosensing of non-coding RNAs for prostate Cancer diagnosis and prognosis
Abstract
Prostate cancer (PCa) is a prevalent malignancy with high mortality, partly due to the lack of reliable diagnostic methods. In recent years, non-coding RNAs (ncRNAs) have gained recognition as promising indicators for accurate disease detection and outcome prediction, given their inherent stability and expression profiles that are specific to pathological states. To enable the measurement of these biomolecules, a range of biosensors especially electrochemical sensing systems have been developed, providing advantages such as high precision in diagnosis, fast response times, and low cost. The present review focuses on the significance of ncRNAs as diagnostic markers for PCa and summarizes recent progress in biosensing technologies, emphasizing electrochemical methods designed to identify ncRNAs associated with this cancer.
Read the paper
Related studies
- Regulation of nucleolus assembly by non-coding RNA polymerase II transcripts
- For a Healthy Histone Code, a Little SUMO in the Tail Keeps the Acetyl Away
- Discovering a binary CTCF code with a little help from BORIS
- Article Commentary: Stabilizing the Code–-Methods to Preserve RNA Prove Their Worth
- Foreword to the Special Issue for the RINTC (The Implicit Seismic Risk of Code-Conforming Structures) Project
- Commentary: Promoting Health and Well-being in Pediatric Primary Care Settings: Using Health and Behavior Codes at Routine Well-child Visits
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.